文献速递烧伤创面修复

重新审视大面积烧伤患者首次阳性培养的经验性抗生素选择

Evaluating First Positive Cultures in Burns: Rethinking Broad-Spectrum Antibiotic Choices.
PubMed 文献 · J Burn Care Res · 2026-01-01

该单中心回顾性研究分析了2018年至2023年加拿大最高容量成人烧伤中心收治的114例≥20%体表面积烧伤患者的145次首次阳性培养的微生物谱与抗生素处方模式。结果显示呼吸道和创面是最常见培养部位,甲氧西林敏感金黄色葡萄球菌最常见,仅3%入院MRSA筛查阴性患者后续出现MRSA阳性培养。哌拉西林-他唑巴坦仍为有效早期经验性用药,但美罗培南或环丙沙星联合头孢唑林可提供 comparable 覆盖,支持抗菌药物管理。

要点

  • 呼吸道(55%)和创面(30%)是首次阳性培养最常见部位。
  • 入院MRSA筛查阴性者后续MRSA阳性培养仅3%,阴性预测值约97%,支持暂缓万古霉素。
  • 哌拉西林-他唑巴坦仍有效,但美罗培南或环丙沙星联合头孢唑林覆盖更广,可作靶向替代。

核心结论

  • 哌拉西林-他唑巴坦仍是大面积烧伤早期经验性治疗的有效选择,但靶向替代方案如美罗培南或环丙沙星联合头孢唑林可提供可比覆盖并促进抗菌药物管理。
  • 入院MRSA筛查阴性对后续MRSA阳性培养具有高阴性预测值(约97%),支持在此类患者中暂缓万古霉素。

研究设计与样本

  • 单中心回顾性研究,纳入2018年1月1日至2023年5月1日加拿大最高容量成人烧伤中心收治的114例≥20%体表面积烧伤患者,分析145次首次阳性培养的微生物谱与抗生素处方模式。

主要发现

  • 145次首次阳性培养中,最常见培养部位为呼吸道(55%)和创面(30%)。
  • 最常见病原体为甲氧西林敏感金黄色葡萄球菌(19%)、流感嗜血杆菌(15%)、阴沟肠杆菌复合群(8%)、大肠埃希菌(7%)、MRSA(7%)和铜绿假单胞菌(6%)。
  • 入院MRSA筛查阴性的患者中仅3%后续出现MRSA阳性培养。
  • 99%的首次阳性培养患者启动抗生素治疗,最常用哌拉西林-他唑巴坦(41%)、万古霉素(16%)和头孢唑林(14%),联合治疗占13%(多为哌拉西林-他唑巴坦联合万古霉素)。
  • 药敏数据显示美罗培南覆盖90%分离株,环丙沙星联合头孢唑林覆盖83%。

关键数值与推荐

  • 美罗培南对分离株的覆盖率为90%,环丙沙星联合头孢唑林为83%。
  • 入院MRSA筛查阴性对后续MRSA阳性培养的阴性预测值约97%。

临床怎么用

  • 对入院MRSA筛查阴性的患者可考虑暂缓万古霉素经验性使用。
  • 在适当患者中可选用环丙沙星联合头孢唑林替代哌拉西林-他唑巴坦,或将美罗培南保留用于特定病例。
  • 应结合本地微生物数据制定抗菌药物管理策略。

局限性

  • 本研究为单中心回顾性设计,结果外推需结合本地流行病学数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infection is a nearly universal complication among patients with major burns, yet guidance on early empiric antibiotic therapy remains limited. Broad-spectrum antibiotics are commonly initiated in the early phase of care but carry risks of antimicrobial resistance and drug toxicities. This single-center, retrospective study evaluated the microbiological profiles and antibiotic prescribing patterns associated with first positive cultures (FPCs) in patients with major burn injuries admitted to Canada's highest-volume adult burn center between January 1, 2018 and May 1, 2023. A total of 114 patients with ≥ 20% total body surface area burns were included. Among 145 FPCs, the most commonly cultured sites were respiratory (55%) and wound (30%). The most frequently identified organisms were methicillin-sensitive Staphylococcus aureus (19%), Haemophilus influenzae (15%), Enterobacter cloacae complex (8%), Escherichia coli (7%), methicillin-resistant S aureus (MRSA) (7%), and Pseudomonas aeruginosa (6%). Notably, only 3% of patients who screened negative for MRSA on admission developed MRSA-positive cultures. Antibiotic therapy was initiated in 99% of patients with FPCs, most commonly with piperacillin-tazobactam (41%), vancomycin (16%), and cefazolin (14%). Dual therapy, typically piperacillin-tazobactam plus vancomycin, was used in 13% of cases. Sensitivity data demonstrated that meropenem (90%) and the combination of ciprofloxacin with cefazolin (83%) covered the highest proportion of isolates. While piperacillin-tazobactam remains effective for early empiric use, our findings indicate that targeted alternatives-such as reserving meropenem for select cases or using ciprofloxacin plus cefazolin in appropriate patients-could provide comparable coverage while adhering to antimicrobial stewardship principles. A negative MRSA screening swab on admission demonstrated a high negative predictive value (~97%), supporting the withholding of vancomycin in screen-negative patients. This study supports evidence-based antibiotic use in patients with burn injuries and underscores the need for local, data-driven stewardship.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Sadeghighazichaki P, Rogers AD, Elligsen M, et al. Evaluating First Positive Cultures in Burns: Rethinking Broad-Spectrum Antibiotic Choices. J Burn Care Res. 2026. PMID: 41410360. doi:10.1093/jbcr/iraf229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。